PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,908 · see citing works

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,665 · see citing works

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184 · see citing works

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Kyriakopoulos, C. E., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,108 · see citing works

German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 849 · see citing works

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810 · see citing works

On the exact distribution of maximally selected rank statistics

Hothorn, T., & Lausen, B. (2003) · Computational Statistics & Data Analysis · doi:10.1016/s0167-9473(02)00225-6 · Cited by 694 · see citing works

Metastatic prostate cancer

Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546 · see citing works

Dosimetry of ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

Violet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504 · cited 2× · see citing works

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7270 · Cited by 461 · see citing works

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)

Kratochwil, C., Fendler, W. P., Eiber, M., Baum, R. P., Bozkurt, M. F., Czernin, J. G., Bolton, R. C. D., Ezziddin, S., Forrer, F., Hicks, R. J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04485-3 · Cited by 387 · see citing works

68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour

Uprimny, C., Kroiss, A. S., Decristoforo, C., Fritz, J., von Guggenberg, E., Kendler, D., Scarpa, L., di Santo, G., Roig, L. G., Maffey-Steffan, J., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3631-6 · Cited by 342 · see citing works

Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Ahmadzadehfar, H., Rahbar, K., Kürpig, S., Bögemann, M., Claesener, M., Eppard, E., Gärtner, F., Rogenhofer, S., Schäfers, M. A., & Essler, M. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0114-2 · Cited by 293 · see citing works

Neuroendocrine differentiation of prostate cancer leads to PSMA suppression

Bakht, M. K., Derecichei, I., Li, Y., Ferraiuolo, R., Dunning, M., Oh, S. W., Hussein, A. A., Youn, H., Stringer, K. F., Jeong, C. W., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0226 · Cited by 191 · see citing works

Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer

Rahbar, K., Bode, A., Weckesser, M., Avramović, N., Claesener, M., Stegger, L., & Bögemann, M. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001240 · Cited by 186 · see citing works

TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)

Hofman, M. S., Emmett, L., Violet, J. A., Zhang, A. Y., Lawrence, N. J., Stockler, M. R., Francis, R. J., Iravani, A., Williams, S., Azad, A., et al. (2019) · British Journal of Urology · doi:10.1111/bju.14876 · Cited by 165 · see citing works

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Ferdinandus, J., Violet, J. A., Sandhu, S. K., Hicks, R. J., Kumar, A. S. R., Iravani, A., Kong, G., Akhurst, T. J., Thang, S. P., Murphy, D. G., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04723-z · Cited by 165 · see citing works

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177 Lu-PSMA-617 Radioligand Therapy

Seifert, R., Seitzer, K. E., Herrmann, K., Kessel, K., Schäfers, M. A., Kleesiek, J., Weckesser, M., Boegemann, M., & Rahbar, K. (2020) · Theranostics · doi:10.7150/thno.47251 · Cited by 138 · see citing works

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models

Denmeade, S. R., Sokoll, L. J., Dalrymple, S. L., Rosen, D. M., Gady, A. M., Bruzek, D. J., Ricklis, R. M., & Isaacs, J. T. (2003) · The Prostate · doi:10.1002/pros.10199 · Cited by 136 · see citing works

Semiautomatically Quantified Tumor Volume Using 68 Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer

Seifert, R., Herrmann, K., Kleesiek, J., Schäfers, M. A., Shah, V. P., Xu, Z., Chabin, G., Grbić, S., Spottiswoode, B. S., & Rahbar, K. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.242057 · Cited by 132 · see citing works

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT

Gafita, A., Bieth, M., Krönke, M., Tetteh, G., Navarro, F., Wang, H., Günther, E., Menze, B. H., Weber, W., & Eiber, M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224055 · Cited by 127 · see citing works

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer

Armstrong, A. J., Anand, A., Edenbrandt, L., Bondesson, E., Bjartell, A. S., Widmark, A., Sternberg, C. N., Пили, Р., Tuvesson, H., Nordle, Ö., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1093 · Cited by 103 · see citing works

Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics

Rahbar, K., Bodei, L., & Morris, M. J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234054 · Cited by 70 · see citing works

Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study

Gafita, A., Fendler, W. P., Wang, H., Sandhu, S. K., Weber, M., Esfandiari, R., Calais, J., Rauscher, I., Rathke, H. G., Tauber, R., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.05.004 · Cited by 62 · see citing works

Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis

Seifert, R., Kessel, K., Schlack, K., Weckesser, M., Bögemann, M., & Rahbar, K. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04703-3 · Cited by 45 · see citing works

TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer.

Hofman, M. S., Emmett, L., Violet, J. A., Lawrence, N. J., Williams, S., Stockler, M. R., Francis, R. J., Iravani, A., Zhang, A. Y., Martin, A. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.tps332 · Cited by 6 · see citing works

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Seifert, R., Emmett, L., Rowe, S. P., Herrmann, K., Hadaschik, B. A., Calais, J., Giesel, F. L., Reiter, R. E., Maurer, T., Heck, M. M., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.02.002 · Cited by 326 · see citing works

Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer

Sayar, E., Patel, R. A., Coleman, I. M., Roudier, M. P., Zhang, A., Mustafi, P., Low, J., Hanratty, B. P., Ang, L. S., Bhatia, V., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.162907 · Cited by 87 · see citing works

Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting

Johnsson, K., Brynolfsson, J., Sahlstedt, H., Nickols, N. G., Rettig, M. B., Probst, S., Morris, M. J., Bjartell, A. S., Eiber, M., & Anand, A. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05497-8 · Cited by 64 · see citing works

Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis

Rosar, F., Krause, J., Bartholomä, M. D., Maus, S., Stemler, T., Hierlmeier, I., Linxweiler, J., Ezziddin, S., & Khreish, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050722 · Cited by 61 · see citing works

177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial

Pathmanandavel, S., Crumbaker, M., Yam, A. O. W., Nguyen, A., Rofe, C., Hovey, E. J., Gedye, C. A., Kwan, E. M., Hauser, C., Azad, A., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262552 · Cited by 60 · see citing works

Applications of Artificial Intelligence in PSMA PET/CT for Prostate Cancer Imaging

Belal, S. L., Frantz, S., Minarik, D., Enqvist, O., Wikström, E., Edenbrandt, L., & Trägårdh, E. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.06.001 · Cited by 58 · see citing works

Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes

Corpetti, M., Müller, C., Beltran, H., Bono, J. S. D., & Theurillat, J.-P. P. (2023) · European Urology · doi:10.1016/j.eururo.2023.11.018 · Cited by 55 · see citing works

Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens

Yazdani, E., Geramifar, P., Ziarati, N. K., Sadeghi, M., Amini, P., & Rahmim, A. (2024) · Diagnostics · doi:10.3390/diagnostics14020181 · Cited by 55 · see citing works

Influences on PET Quantification and Interpretation

Rogasch, J. M. M., Hofheinz, F., van Heek, L., Voltin, C.-A., Boellaard, R., & Kobe, C. (2022) · Diagnostics · doi:10.3390/diagnostics12020451 · Cited by 50 · see citing works

Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy

Seifert, R., Kessel, K., Schlack, K., Weckesser, M., Kersting, D., Seitzer, K. E., Weber, M., Bögemann, M., & Rahbar, K. (2021) · Theranostics · doi:10.7150/thno.60222 · Cited by 50 · see citing works

A Prognostic Risk Score for Prostate Cancer Based on PSMA PET–derived Organ-specific Tumor Volumes

Seifert, R., Rasul, S., Seitzer, K. E., Eveslage, M., Nikoukar, L. R., Kessel, K., Schäfers, M. A., Yu, J., Haug, A. R., Hacker, M., et al. (2023) · Radiology · doi:10.1148/radiol.222010 · Cited by 48 · see citing works

Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria

Michalski, K., Klein, C., Brüggemann, T., Meyer, P. T., Jilg, C. A., & Ruf, J. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.260836 · Cited by 48 · see citing works

Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning

Capobianco, N., Sibille, L., Chantadisai, M., Gafita, A., Langbein, T., Platsch, G., Solari, E. L., Shah, V. P., Spottiswoode, B. S., Eiber, M., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05473-2 · Cited by 46 · see citing works

Fully automatic prognostic biomarker extraction from metastatic prostate lesion segmentations in whole-body [68Ga]Ga-PSMA-11 PET/CT images

Kendrick, J., Francis, R. J., Hassan, G. M., Rowshanfarzad, P., Ong, J. S. L., & Ebert, M. A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05927-1 · Cited by 46 · see citing works

Clinical Use of PET/MR in Oncology: An Update

Seifert, R., Kersting, D., Rischpler, C., Opitz, M. K., Kirchner, J., Pabst, K. M., Mavroeidi, I. A., Laschinsky, C., Grueneisen, J. S., Schaarschmidt, B. M., et al. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2021.11.012 · Cited by 46 · see citing works

Is 18 F-FDG PET Needed to Assess 177 Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis

Seifert, R., Telli, T., Hadaschik, B. A., Fendler, W. P., Kuo, P. H., & Herrmann, K. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264741 · Cited by 47 · see citing works

SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T

Hartrampf, P. E., Hüttmann, T., Seitz, A. K., Kübler, H. R., Serfling, S. E., Schlötelburg, W., Michalski, K., Rowe, S. P., Pomper, M. G., Buck, A. K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06281-6 · Cited by 43 · see citing works

Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond

Gafita, A., Marcus, C. V., Kostos, L. K., Schuster, D. M., Calais, J., & Hofman, M. S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_350946 · Cited by 44 · see citing works

PSMA Theranostics: Science and Practice

Mokoala, K. M. G., Lawal, I. O., Lengana, T., Kgatle, M., Giesel, F. L., Vorster, M., & Sathekge, M. M. (2021) · Cancers · doi:10.3390/cancers13153904 · Cited by 43 · see citing works

Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis

von Eyben, F. E., Bauman, G. S., von Eyben, R., Rahbar, K., Soydal, Ç., Haug, A. R., Virgolini, I. J., Kulkarni, H., Baum, R. P., & Paganelli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239054 · Cited by 40 · see citing works

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

Emmett, L., Papa, N., Subramaniam, S., Crumbaker, M., Nguyen, A. D. K., Joshua, A. M., Sandhu, S., Weickhardt, A., Lee, S.-T., Ng, S., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00339-0 · Cited by 39 · see citing works

The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study

Ahmadzadehfar, H., Matern, R., Baum, R. P., Seifert, R., Kessel, K., Bögemann, M., Kratochwil, C., Rathke, H. G., Ilhan, H., Svirydenka, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05383-3 · Cited by 38 · see citing works

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer

Luining, W. I., Cysouw, M. C. F., Meijer, D., Hendrikse, N. H., Boellaard, R., Vis, A. N., & Oprea‐Lager, D. E. (2022) · Cancers · doi:10.3390/cancers14051169 · Cited by 38 · see citing works

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy

Widjaja, L., Werner, R. A., Roß, T. L., Bengel, F. M., & Derlin, T. (2021) · Cancers · doi:10.3390/cancers13122938 · Cited by 36 · see citing works

Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis

Roll, W., Schindler, P., Masthoff, M., Seifert, R., Schlack, K., Bögemann, M., Stegger, L., Weckesser, M., & Rahbar, K. (2021) · Cancers · doi:10.3390/cancers13153849 · Cited by 36 · see citing works

Prostate Cancer Theranostics

Seifert, R., Alberts, I., Afshar‐Oromieh, A., & Rahbar, K. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.03.004 · Cited by 35 · see citing works

SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis

Herrmann, K., Walz, J. C., MacLennan, S., Briganti, A., Cornford, P. A., Czernin, J. G., Eiber, M. J., Fanti, S., Fendler, W. P., Fizazi, K. S., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.08.005 · Cited by 36 · see citing works

Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians

Trägårdh, E., Enqvist, O., Ulén, J., Hvittfeldt, E., Garpered, S., Belal, S. L., Bjartell, A. S., & Edenbrandt, L. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05806-9 · Cited by 34 · see citing works

Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer

Unterrainer, L. M., Calais, J., & Bander, N. H. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-081522-031439 · Cited by 32 · see citing works

Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients

Mittlmeier, L. M., Brendel, M., Beyer, L., Albert, N. L., Todica, A. S., Zacherl, M. J., Wenter, V., Herlemann, A., Kretschmer, A., Ledderose, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.663631 · Cited by 31 · see citing works

A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Wang, G.-C., Zang, J., Jiang, Y.-Y., Liu, Q., Sui, H., Wang, R., Fan, X., Zhang, J., Zhu, Z.-H., & Chen, X.-Y. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264857 · Cited by 32 · see citing works

PSMA-targeted therapy for non-prostate cancers

Wang, J. H., & Kiess, A. P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1220586 · Cited by 30 · see citing works

Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer

Sun, Y., Chen, G., He, J., Huang, Z., Li, S., Yang, Y., Zhong, L.-Y., Ji, S.-F., Huang, Y., Chen, X., et al. (2020) · Bioengineered · doi:10.1080/21655979.2020.1867405 · Cited by 29 · see citing works

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

Heidegger, I. M., Kesch, C. V., Kretschmer, A., Tsaur, I., Ceci, F., Massimo Valerio, A., Derya Tilki, A., Marra, G., Preißer, F., Fankhauser, C. D., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221081922 · Cited by 29 · see citing works

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study

Karpinski, M. J., Rahbar, K., Bögemann, M., Nikoukar, L. R., Schäfers, M. A., Hoberück, S., Miederer, M., Hölscher, T., Rasul, S., Miszczyk, M., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.04.017 · Cited by 29 · see citing works

Prostate Cancer Theranostics With 177Lu-PSMA

Ahmadzadehfar, H., Seifert, R., Afshar‐Oromieh, A., Kratochwil, C., & Rahbar, K. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.02.007 · Cited by 26 · see citing works

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives

Seifert, K. E., Seifert, R., Kessel, K., Roll, W., Schlack, K., Boegemann, M., & Rahbar, K. (2021) · Cancers · doi:10.3390/cancers13153715 · Cited by 25 · see citing works

Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T

Unterrainer, L. M., Beyer, L., Zacherl, M. J., Gildehaus, F. J., Todica, A. S., Kunte, S. C., Holzgreve, A., Sheikh, G. T., Herlemann, A., Casuscelli, J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10050946 · Cited by 25 · see citing works

Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours

Wang, Q., & Zhang, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114690 · Cited by 25 · see citing works

Prognostic Value of PSMA PET/CT in Prostate Cancer

Lawal, I. O., Ndlovu, H., Kgatle, M., Mokoala, K. M. G., & Sathekge, M. M. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.07.003 · Cited by 25 · see citing works

Comparison of parametric imaging and SUV imaging with [68 Ga]Ga-PSMA-11 using dynamic total-body PET/CT in prostate cancer

Chen, R., Ng, Y. L., Yang, X., Zhu, Y., Li, L., Zhao, H., Zhou, Y., Huang, G., & Liu, J. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06456-1 · Cited by 25 · see citing works

Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer

Hong, S., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Shah, J. C., Bergstrom, C. P., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06718-6 · Cited by 26 · see citing works

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received177Lu-PSMA-617: Importance of18F-FDG–Avid Discordant Findings

Demirci, R. A., Ghodsi, A., Gulati, R., Behnia, F., Nelson, P. S., Cheng, H. H., Yezefski, T., Haffner, M. C., Hawley, J. E., Montgomery, B., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268167 · Cited by 24 · see citing works

New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177)

Zha, Z., Choi, S., Li, L., Zhao, R., Plöessl, K., Yao, X., Alexoff, D., Zhu, L., & Kung, H. F. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00852 · Cited by 22 · see citing works

177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers

Giunta, E. F., Brighi, N., Gurioli, G., Matteucci, F., Paganelli, G., & Giorgi, U. D. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102699 · Cited by 22 · see citing works

Morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review

Collins, K., & Liang Cheng, C. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.06.004 · Cited by 21 · see citing works

First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes

Lang, D., Ritzberger, L., Rambousek, V., Horner, A., Wass, R. E., Akbari, K., Kaiser, B., Kronbichler, J., Lamprecht, B., & Gabriel, M. (2021) · Cancers · doi:10.3390/cancers13236096 · Cited by 20 · see citing works

Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?

Şimşek, D. H., Kuyumcu, S., Karadogan, S., Oflas, M., Işık, E. G., Özkan, Z. G., Paksoy, N., Ekmekçioğlu, Ö., Ekenel, M., & Şanlı, Y. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01610-x · Cited by 20 · see citing works

Outcome of 177Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters

Şimşek, D. H., Kuyumcu, S., Karadogan, S., Özkan, Z. G., Işık, E. G., Başaran, M., Şanlı, Ö., & Şanlı, Y. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004222 · Cited by 19 · see citing works

Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer

Peterson, J. R., Cole, J. A., Pfeiffer, J. R., Norris, G. H., Zhang, Y., Lopez-Ramos, D., Pandey, T., Biancalana, M., Esslinger, H. R., Antony, A. K., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01654-z · Cited by 18 · see citing works

Enhancing precision: A predictive model for 177Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative 68Ga-DOTATATE PET and clinicopathological biomarkers

Akhavanallaf, A., Joshi, S., Mohan, A., Worden, F. P., Krauss, J. C., Zaidi, H., Frey, K. A., Suresh, K., Dewaraja, Y. K., & Wong, K. K. (2024) · Theranostics · doi:10.7150/thno.98053 · Cited by 18 · see citing works

PSMA‐Hornet: Fully‐automated, multi‐target segmentation of healthy organs in PSMA PET/CT images

Klyuzhin, I. S., Chaussé, G., Bloise, I., Harsini, S., Ferres, J. L., Uribe, C., & Rahmim, A. (2023) · Medical Physics · doi:10.1002/mp.16658 · Cited by 17 · see citing works

Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer

Shah, H., Ravi, P. K., Sonpavde, G., & Jacene, H. A. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2139679 · Cited by 16 · see citing works

Standardized PSMA-PET Imaging of Advanced Prostate Cancer

Seifert, R., Gafita, A., Telli, T., Voter, A. F., Herrmann, K., Pomper, M. G., Hadaschik, B. A., Rowe, S. P., & Fendler, W. P. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.07.005 · Cited by 15 · see citing works

Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry

Burgard, C., Hein, C., Blickle, A., Bartholomä, M. D., Maus, S., Petto, S., Schaefer-Schuler, A., Ezziddin, S., & Rosar, F. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06476-x · Cited by 15 · see citing works

Fully automated volumetric assessment of tumor burden using artificial intelligence on 68Ga-PSMA-11 PET predicts survival after 177Lu-PSMA therapy in metastatic Castration-resistant prostate cancer

Zang, S., Meng, Q., Li, X., Guo, T., Zhang, L., Zhao, Z., Yu, F., Zhang, P., Wu, W., Ni, Y., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07628-x · Cited by 16 · see citing works

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective

Ng, T. S. C., Gao, X., Salari, K., Zlatev, D. V., Heidari, P., & Kamran, S. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722277 · Cited by 14 · see citing works

Role of volumetric parameters obtained from 68 Ga-PSMA PET/CT and 18F-FDG PET/CT in predicting overall survival in patients with mCRPC receiving taxane therapy

Güzel, Y., Kömek, H., Can, C., Kaplan, İ., Akdeniz, N., Kepenek, F., & Gündoğan, C. (2023) · Annals of Nuclear Medicine · doi:10.1007/s12149-023-01854-9 · Cited by 14 · see citing works

The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer

Saffar, H. A., Chen, D. C., Delgado, C., Ingvar, J., Hofman, M. S., Lawrentschuk, N., Perera, M., Murphy, D. G., & Eapen, R. S. (2024) · Cancers · doi:10.3390/cancers16050939 · Cited by 14 · see citing works

Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer—a cross-sectional study

Kluge, K., Einspieler, H., Haberl, D., Spielvogel, C. P., Amereller, D., Egger, G., Kramer, G., Grubmüller, B., Shariat, S. F., Hacker, M., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06698-7 · Cited by 13 · see citing works

Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview

Caracciolo, M., Castello, A., Castellani, M., Bartolomei, M., & Lopci, E. (2024) · Biomedicines · doi:10.3390/biomedicines12102355 · Cited by 13 · see citing works

Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study

Hu, J., Seifert, R., Karkampouna, S., Gomes, C. V., Xue, S., Afshar‐Oromieh, A., Rominger, A., & Shi, K. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07010-3 · Cited by 13 · see citing works

The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy

Murthy, V., Ludwig, V. B., Gafita, A., Hope, T. A., & Calais, J. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268818 · Cited by 13 · see citing works

Repeatability of 68Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume

Seifert, R., Sandach, P., Kersting, D., Fendler, W. P., Hadaschik, B. A., Herrmann, K., Sunderland, J. J., & Pollard, J. H. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262528 · Cited by 13 · see citing works

Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value

Andela, S. B., Amthauer, H., Furth, C., Rogasch, J. M. M., Beck, M., Mehrhof, F. B., Ghadjar, P., van den Hoff, J., Klatte, T., Tahbaz, R., et al. (2024) · Radiation Oncology · doi:10.1186/s13014-024-02483-w · Cited by 12 · see citing works

To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy

Srinivas, S., & Iagaru, A. H. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263035 · Cited by 12 · see citing works

Recent advances in the molecular targeted drugs for prostate cancer

Gao, P., Li, T., Zhang, K., & Luo, G. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03487-3 · Cited by 12 · see citing works

Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel

Shagera, Q. A., Karfis, I., Sideris, S., Guiot, T., Woff, E., Chanzá, N. M., Roumeguère, T., Gil, T., Flamen, P., & Artigas, C. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004763 · Cited by 11 · see citing works

Outcomes and prognostic predictors of Lu‐177 PSMA radioligand therapy in metastatic castration‐resistant prostate cancer (Asian Population Study)

Chua, W. M., Lam, W. W.-C., Tong, A. K. T., Sultana, R., Kua, S. M. Y., Kanesvaran, R., Wong, A. S. C., Tay, K. J., Cheng, T. J. L., Ng, D. C. E., et al. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13944 · Cited by 10 · see citing works

Is There a Role of Artificial Intelligence in Preclinical Imaging?

Küper, A. T., Blanc‐Durand, P., Gafita, A., Kersting, D., Fendler, W. P., Seibold, C., Moraitis, A., Lückerath, K., James, M. L., & Seifert, R. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.03.003 · Cited by 10 · see citing works

A fully automated AI-based method for tumour detection and quantification on [18F]PSMA-1007 PET–CT images in prostate cancer

Trägårdh, E., Ulén, J., Enqvist, O., Larsson, M., Valind, K., Minarik, D., & Edenbrandt, L. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00786-9 · Cited by 10 · see citing works

Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment

Telli, T. A., Özgüven, S., Alan, Ö., Filizoğlu, N., Öztürk, M. A., Busery, N. S., Işık, S., Arıkan, R., Demircan, N. C., Başoğlu, T., et al. (2022) · Annals of Nuclear Medicine · doi:10.1007/s12149-022-01785-x · Cited by 10 · see citing works

Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics

Eshghi, A., Covington, M. F., Eshghi, N., & Kuo, P. H. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004196 · Cited by 10 · see citing works

Advances in PSMA Alpha Theragnostics

Vorster, M., & Sathekge, M. M. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.03.004 · Cited by 9 · see citing works

Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?

Franco, M. D., Mei, R., Garcia, C., & Fanti, S. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241258367 · Cited by 8 · see citing works

Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI

Kersting, D., Borys, K., Küper, A. T., Kim, M., Haubold, J., Goerttler, T., Umutlu, L., Costa, P. F., Kleesiek, J., Rischpler, C., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07060-7 · Cited by 11 · see citing works

Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy

Santoro-Fernandes, V., Schott, B., Weisman, A. J., Lokre, O., Cho, S. Y., Perlman, S. B., Perk, T., & Jeraj, R. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267809 · Cited by 9 · see citing works

177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements

Cao, J., Chen, Y., Hu, M. L., & Zhang, W. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01649-w · Cited by 9 · see citing works

Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer

Schneider, C., Täger, P., Hammes, J., Fischer, T. H., Drzezga, A. E., Pfister, D. J. K. P., Heidenreich, A., & Schmidt, M. C. (2021) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-1670-9500 · Cited by 9 · see citing works

PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy

Oldan, J., Almaguel, F., Voter, A. F., Durán, A., Gafita, A., Pomper, M., Hope, T., & Rowe, S. P. (2024) · Cancer Journal · doi:10.1097/ppo.0000000000000718 · Cited by 5 · see citing works

Single Center Experience with a 4-Week 177Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer

Kemppainen, J., Kangasmäki, A., Malaspina, S., Pape, B., Jalomäki, J., Kairemo, K., Kononen, J., & Joensuu, T. K. (2022) · Cancers · doi:10.3390/cancers14246155 · Cited by 8 · see citing works

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [177Lu]Lu-PSMA-617 Radioligand Therapy

Siripongsatian, D., Jantarato, A., Promteangtrong, C., Kunawudhi, A., Kiatkittikul, P., Boonkawin, N., Yaset, S., Somboon, S., & Chotipanich, C. (2024) · Indian journal of radiology and imaging - new series/Indian journal of radiology and imaging/Indian Journal of Radiology & Imaging · doi:10.1055/s-0044-1779634 · Cited by 7 · see citing works

Investigating the significance of SPECT/CT-SUV for monitoring 177Lu-PSMA-targeted radionuclide therapy: a systematic review

Alkahtani, T. O. (2025) · BMC Medical Imaging · doi:10.1186/s12880-025-01571-x · Cited by 7 · see citing works

Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [⁶⁸Ga]Ga-PSMA-11 PET/CT study

Kluge, K., Lotz, V., Einspieler, H., Haberl, D., Spielvogel, C. P., Amereller, D., Kramer, G., Grubmüller, B., Shariat, S. F., Haug, A. R., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01811-5 · Cited by 7 · see citing works

Refining the clinical utility of [177Lu]Lu/[225Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer

Widjaja, L., Hornfeck, J., Siegmund, S. C., Gildehaus, F. J., Schmidt-Hegemann, N.-S., Wenter, V., Sheikh, G. T., Klimek, K., Casuscelli, J., Stief, C. G., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07632-1 · Cited by 7 · see citing works

Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CT

Molin, K., Barry, N., Gill, S., Hassan, G. M., Francis, R. J., Ong, J. S. L., Ebert, M. A., & Kendrick, J. (2025) · Physical and Engineering Sciences in Medicine · doi:10.1007/s13246-024-01516-8 · Cited by 6 · see citing works

Prognostic [68Ga]Ga‐PSMA‐11 PET Biomarkers for [177Lu]Lu‐PSMA Radioligand Therapy in Metastatic Castrate‐Resistant Prostate Cancer (Asian Population Study)

Koh, N., Wei, M.-C., Lam, W., Tong, A., Kanesvaran, R., Wong, A., Chen, K., & Thang, S. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14174 · Cited by 5 · see citing works

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study

Zamanian, A., Rousseau, É., Buteau, F.-A., Arsenault, F., Beaulieu, A., April, G., Juneau, D., Plouznikoff, N., Turcotte, É. E., Allard, C., et al. (2025) · Cancer Imaging · doi:10.1186/s40644-025-00910-z · Cited by 6 · see citing works

Quantitative PSMA PET Biomarkers for Predicting Response to 177 Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis

Kiani, I., Siri, M. A., Babaei, M., Aliasghari, M. M., Mohammadzadeh, S., Mohammadi, S., & Salavati, A. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270872 · Cited by 6 · see citing works

Theranostics in oncology: What radiologists want to know

Ferdinandus, J., Fendler, W. P., Morigi, J. J., & Fanti, S. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.109875 · Cited by 6 · see citing works

Prognostic 18F-flotufolastat PET parameters for outcome assessment of 177Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer

Karimzadeh, A., Hansen, K., Hasa, E., Haller, B., Heck, M. M., Tauber, R., D’Alessandria, C., Weber, W., Eiber, M., & Rauscher, I. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07003-2 · Cited by 5 · see citing works

Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [ 177 Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy, V., Kimura, K., Theus, L., Nguyen, A., Grogan, T., Lokre, O., Perk, T., Rettig, M. B., Drakaki, A., Shen, J., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270916 · Cited by 5 · see citing works

PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617

Ghodsi, A., Owens, L., Demirci, R. A., Gafita, A., Cheng, H. H., Hawley, J. E., Raychaudhuri, R., Khan, H. M., Sunkara, R., Hsieh, A. C., et al. (2026) · Radiology · doi:10.1148/radiol.250649 · Cited by 5 · see citing works

Utility of PSMA-PET derived volumetric parameters in initial risk stratification and prediction of prostate cancer metastasis – a head-to-head comparison of the radiotracers 18F-PSMA-1007 and 68Ga-PSMA-11

Chandekar, K. R., Satapathy, S., Singh, H., Kumar, R., Kumar, S., Kakkar, N., Mittal, B. R., & Singh, S. K. (2024) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001874 · Cited by 5 · see citing works

Prognostic value of body composition out of PSMA-PET/CT in prostate cancer patients undergoing PSMA-therapy

Roll, W., Plagwitz, L., Ventura, D., Masthoff, M., Backhaus, C., Varghese, J., Rahbar, K., & Schindler, P. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07416-7 · Cited by 5 · see citing works

Update on radioligand therapy with 177 Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects

Fuoco, V., Argiroffi, G., Mazzaglia, S., Lorenzoni, A., Guadalupi, V., Franza, A., Scalorbi, F., Aliberti, G., Chiesa, C., Procopio, G., et al. (2021) · Tumori Journal · doi:10.1177/03008916211037732 · Cited by 5 · see citing works

Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease

Yechiel, Y., Orr, Y., Gurevich, K., Gill, R., & Keidar, Z. (2023) · Cancers · doi:10.3390/cancers15041020 · Cited by 5 · see citing works

Tumor Volume Is a Better Prognostic Factor than Greatest Tumor Diameter in Operated Stage I-III Non–Small-Cell Lung Cancer

Duran, A. O., İnanç, M., Bozkurt, O., Özaslan, E., & Özkan, M. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.02.009 · Cited by 5 · see citing works

Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling

Siebinga, H., Hendrikx, J. J. M. A., Huitema, A. D. R., & der Veen, B. J. D. W. (2023) · EJNMMI Research · doi:10.1186/s13550-023-01008-y · Cited by 4 · see citing works

Diffuse Bone Marrow Involvement of Multiple Myeloma on [18F]PSMA-1007 PET/CT

Michalski, K., Jilg, C. A., Engelhardt, M. M., Meyer, P. T., & Ruf, J. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004286 · Cited by 4 · see citing works

Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy

Seifert, R., Kessel, K., Schlack, K., Weckesser, M., Kersting, D., Seitzer, K. E., Weber, M., Bögemann, M., & Rahbar, K. (2021) · Theranostics · doi:10.7150/thno.60222 · Cited by 50 · see citing works

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177 Lu-PSMA-617 Radioligand Therapy

Seifert, R., Seitzer, K. E., Herrmann, K., Kessel, K., Schäfers, M. A., Kleesiek, J., Weckesser, M., Boegemann, M., & Rahbar, K. (2020) · Theranostics · doi:10.7150/thno.47251 · Cited by 138 · see citing works

Pre-therapeutic PSMA PET Imaging Biomarkers Demonstrate Prognostic Value in Patients Undergoing [177Lu]Lu-PSMA Therapy: A Systematic Review and Meta-analysis

Molin, K., Li, S., Barry, N., Ong, J. S. L., Iravani, A., Hofman, M. S., Hassan, G. M., Ebert, M. A., & Kendrick, J. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102628

Predictive value of interim PSMA PET during 177Lu-PSMA radioligand therapy for overall survival in patients with advanced prostate cancer

Gafita, A., Weber, W., Tauber, R., & Eiber, M. (2019) · mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) · Cited by 1 · see citing works

PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617

Ghodsi, A., Owens, L., Demirci, R. A., Gafita, A., Cheng, H. H., Hawley, J. E., Raychaudhuri, R., Khan, H. M., Sunkara, R., Hsieh, A. C., et al. (2026) · Radiology · doi:10.1148/radiol.250649 · Cited by 5 · see citing works